Free Trial
NASDAQ:CMND

Clearmind Medicine (CMND) Stock Price, News & Analysis

Clearmind Medicine logo
$6.19 -0.04 (-0.64%)
As of 02:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Clearmind Medicine Stock (NASDAQ:CMND)

Advanced

Key Stats

Today's Range
$6.20
▼
$6.47
50-Day Range
$5.72
▼
$15.68
52-Week Range
$5.25
▼
$3,840.00
Volume
7,481 shs
Average Volume
117,022 shs
Market Capitalization
$3.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clearmind Medicine Inc. (NASDAQ: CMND) is a clinical-stage biotechnology company developing psychedelic-derived therapeutics for underserved health conditions. The company’s research focuses on creating proprietary compounds designed to address disorders involving addictive and compulsive behaviors.

Clearmind’s lead research program centers on MEAI, a proprietary psychedelic molecule being evaluated for potential use in alcohol use disorder and binge-related behaviors. The company has also investigated additional applications for its compounds, including treatments for obesity and other conditions associated with abnormal consumption patterns.

Clearmind advances its programs through preclinical research, intellectual-property development and clinical testing, with the goal of establishing new pharmaceutical treatments rather than providing psychedelic services directly. The company is headquartered in Israel and operates as a biotechnology developer serving the global pharmaceutical and healthcare markets.

AI Generated. May Contain Errors.

Clearmind Medicine Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

CMND MarketRank™: 
1.0101076398 of 5 stars

Clearmind Medicine scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Clearmind Medicine.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Clearmind Medicine is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Clearmind Medicine is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Clearmind Medicine has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.40% of the float of Clearmind Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Clearmind Medicine has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clearmind Medicine has recently decreased by 58.53%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Clearmind Medicine does not currently pay a dividend.

  • Dividend Growth

    Clearmind Medicine does not have a long track record of dividend growth.

  • News Sentiment

    Clearmind Medicine has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Clearmind Medicine this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Clearmind Medicine insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Clearmind Medicine's insider trading history.
Receive CMND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CMND Stock News Headlines

INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.tc pixel
See More Headlines

CMND Stock Analysis - Frequently Asked Questions

Clearmind Medicine's stock was trading at $144.80 at the beginning of the year. Since then, CMND stock has decreased by 95.7% and is now trading at $6.23.

Clearmind Medicine Inc. (NASDAQ:CMND) posted its earnings results on Thursday, September, 10th. The company reported ($4.56) EPS for the quarter.

Shares of Clearmind Medicine reverse split before market open on Tuesday, November 28th 2023.The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Clearmind Medicine (CMND) raised $9 million in an initial public offering on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. acted as the underwriter for the IPO.

Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
9/10/2026
Today
10/14/2026
Fiscal Year End
10/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CMND
CIK
1892500
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($40.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.86 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-88.53%
Return on Assets
-61.62%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
4.31
Quick Ratio
4.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$115.32 per share
Price / Book
0.05

Miscellaneous

Outstanding Shares
510,000
Free Float
N/A
Market Cap
$3.16 million
Optionable
Not Optionable
Beta
0.93
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:CMND) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners